Nuvectis Pharma will showcase five presentations on their novel SRC/YES1 inhibitor NXP900 at the 2025 AACR Meeting in Chicago from April 25-30, highlighting its potential in multiple cancer types.
Nuvectis Pharma's NXP800 demonstrates antitumor activity in a Phase 1b study for ARID1a-mutated ovarian cancer resistant to platinum-based chemotherapy.
Nuvectis Pharma reported a net loss of $4.2 million for the quarter ended September 30, 2024, a decrease of $1.7 million compared to the same period in 2023.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.